The popularity of online pharmacies is growing at an unprecedented rate in the anticoagulants market, and these channels are projected to emerge as the standard distribution channel in the future. A rapid rise in sales from these channels is also attributable to the increasing demand for effective anticoagulant drugs in developing countries, which is influencing players in the anticoagulants market to target untapped countries with minimal investments in distribution establishments. However, frequent instances of patent expiry are offering a leeway to generic drugs, which is projected to impede the advancement of the anticoagulants market during the forecast period (2020-2026).
The aforementioned insights are explored comprehensively, along with accurate data, in an exclusive study published by Fact.MR. According to the report, the anticoagulants market is projected to trace a healthy growth trajectory, and grow ~1.6X during 2020-2026.
The anticoagulants market report highlights the following players:
- Bayer AG
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company, Limited
- Others
The anticoagulants market report examines the operating pattern of each player – new product launches, partnerships, and acquisitions – has been examined in detail.
Important regions covered in the anticoagulants market report include:
- North America (Canada, US)
- Latin America (Argentina, Mexico)
- Europe (NORDIC, UK)
- Japan and MEA
- APEJ (China, India)
About the Healthcare Division at Fact.MR
The healthcare team at Fact.MR assists clients with unique business intelligence needs on a global level. With a repertoire of over 1,000 reports and 1 million+ data points, the team has analyzed the healthcare industry to the micro-level across 50+ countries for over a decade. The team provides end-to-end research and consulting services to help keep clients at the top of the game. Reach out to us to know how we can help.
You can Request an Example Copy from here - https://www.factmr.com/connectus/sample?flag=S&rep_id=4335
Patient-Assistance Programs to Reinforce Anticoagulant Usage
It has been examined that players operating in the anticoagulants market are supporting initiatives to shoulder the financial affliction of individuals via patient-assistance programs. This is seen as an instrument to enhance the exposure of anticoagulants. For example, Bristol-Myers Squibb provides financial aid to patients so that they can buy medicines through the company’s foundation. However, this program delivers assistance only to those folks who are citizens of the U.S. and are not insured by any publicly- or privately-held company. The report stresses on the fact that increase in the count of manufacturers supporting financial initiatives is likely to lift the adoption of drugs during the forecast period.
These are usually utilized in the treatment of DVT (deep vein thrombosis), atrial fibrillation, pneumonic embolism as well as managing moderate and high danger of stroke.Anticoagulants are essentially segmented as warfarin, therapies, LMWHs (low molecular weight heparins), DTIs (direct thrombin inhibitors) and factor Xa inhibitors.
Of these, the heparin is an injectable anticoagulant broadly utilized in hospitals for fast anticoagulation.
In terms of the types of anticoagulants, the worldwide market is categorized into Dabigatran (Pradaxa), Betrixaban, E Eliquis (Apixaban) Rivaroxaban (Xarelto), as well as doxaban, The application category is additionally subcategorized into heart valve replacement, DVT, myocardial infarction, cardiac arrhythmia, coronary artery diseases, and cardiovascular diseases.On the basis of geography, North America regional market for anticoagulants is considered to foresee a huge market attractiveness.
The U.S. is believed to be the foremost regional market for anticoagulants in North America, trained by Canada.
In Europe, the U.K., France, and Germany account for the majority of the overall market shares of the anticoagulants.
This is due to a bunch of market players are establishing production facilities in the region.
